Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature

Cetuximab is an approved treatment for metastatic colorectal carcinoma (mCRC) with codon 12/13-KRAS mutations, recently questioned for its validity, and alternative mutation-based biomarkers were proposed. We set out to investigate whether an expression signature can also predict response by utilizi...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Sheng, Chen, Dawei, Huang, Xuesong, Cai, Jie, Wery, Jean-Pierre, Li, Qi-Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226604/
https://www.ncbi.nlm.nih.gov/pubmed/27409671
http://dx.doi.org/10.18632/oncotarget.10499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226604/
https://www.ncbi.nlm.nih.gov/pubmed/27409671
http://dx.doi.org/10.18632/oncotarget.10499

Ejemplares similares